DexCom, Inc. (DXCM)
NASDAQ: DXCM · Real-Time Price · USD
82.04
+0.43 (0.53%)
At close: Nov 17, 2026, 4:00 PM EST
81.80
-0.24 (-0.29%)
Pre-market: Nov 18, 2026, 4:06 AM EST
DexCom Revenue
DexCom had revenue of $1.34B in the quarter ending September 30, 2026, with 11.18% growth. This brings the company's total for the last twelve months to $5.10B, up 13.03% year-over-year. In the year 2025, DexCom had annual revenue of $4.66B with 15.60% growth. That makes DexCom the 2,601st largest company in the world by revenue and 759th in the United States.
Revenue (ttm)
$5.10B
Revenue Growth
+13.03%
P/S Ratio
5.99
Revenue / Employee
$459,856
Employees
11,100
Market Cap
30.60B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full DexCom breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.66B | 629.00M | 15.60% |
| Dec 31, 2024 | 4.03B | 410.70M | 11.34% |
| Dec 31, 2023 | 3.62B | 712.50M | 24.49% |
| Dec 31, 2022 | 2.91B | 461.30M | 18.84% |
| Dec 31, 2021 | 2.45B | 521.80M | 27.08% |
| Dec 31, 2020 | 1.93B | 450.70M | 30.54% |
| Dec 31, 2019 | 1.48B | 444.40M | 43.08% |
| Dec 31, 2018 | 1.03B | 313.10M | 43.58% |
| Dec 31, 2017 | 718.50M | 145.20M | 25.33% |
| Dec 31, 2016 | 573.30M | 171.30M | 42.61% |
| Dec 31, 2015 | 402.00M | 142.80M | 55.09% |
| Dec 31, 2014 | 259.20M | 99.20M | 62.00% |
| Dec 31, 2013 | 160.00M | 60.10M | 60.16% |
| Dec 31, 2012 | 99.90M | 23.60M | 30.93% |
| Dec 31, 2011 | 76.30M | 27.70M | 57.00% |
| Dec 31, 2010 | 48.60M | 18.91M | 63.67% |
| Dec 31, 2009 | 29.69M | 19.86M | 201.82% |
| Dec 31, 2008 | 9.84M | 5.21M | 112.62% |
| Dec 31, 2007 | 4.63M | 2.46M | 113.23% |
| Dec 31, 2006 | 2.17M | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GE HealthCare Technologies | 21.64B |
| Boston Scientific | 21.07B |
| Koninklijke Philips | 20.16B |
| Zimmer Biomet Holdings | 8.57B |
| Edwards Lifesciences | 6.67B |
| Smith & Nephew | 6.30B |
| STERIS | 6.17B |
| Insulet | 3.19B |
DXCM News
- 19 hours ago - DexCom Transcript: Jefferies Global Healthcare Conference - Transcripts
- 7 days ago - Dexcom Announces Upcoming Conference Presentation - Business Wire
- 15 days ago - DexCom launches ‘A Letter to Diabetes’ campaign - TheFly
- 15 days ago - Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign - Business Wire
- 18 days ago - DexCom price target raised to $85 from $82 at JPMorgan - TheFly
- 18 days ago - DexCom price target raised to $97 from $94 at Raymond James - TheFly
- 18 days ago - DexCom price target raised to $93 from $82 at StoneX - TheFly
- 18 days ago - DexCom price target raised to $107 from $102 at UBS - TheFly